WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012122282) LOW CELL TOXICITY ANTIBIOTIC HYGROMYCIN B
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2012/122282 International Application No.: PCT/US2012/028091
Publication Date: 13.09.2012 International Filing Date: 07.03.2012
IPC:
C07H 15/224 (2006.01) ,C07H 1/08 (2006.01) ,A61K 31/7036 (2006.01) ,A61P 31/04 (2006.01)
Applicants: PAN, Qiubao[CN/SG]; SG (UsOnly)
TOKU-E COMPANY[US/US]; 715 West Orchard Drive Suite 3 Bellingham, Washington 98225, US (AllExceptUS)
Inventors: PAN, Qiubao; SG
Agent: ENFIELD, David, L.; Seed Intellectual Property Law Group PLLC Suite 5400 701 Fifth Avenue Seattle, Washington 98104-7064, US
Priority Data:
61/450,49008.03.2011US
Title (EN) LOW CELL TOXICITY ANTIBIOTIC HYGROMYCIN B
(FR) HYGROMYCINE B ANTIBIOTIQUE PRÉSENTANT UNE FAIBLE TOXICITÉ CELLULAIRE
Abstract: front page image
(EN) A preparation of antibiotic hygromycin B with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic hygromycin B with a purity of greater than 98% and impurities C, D and E individually less than 0.5% and impurity F less than 2%, as measured by HPLC, is described. Uses of this high purity antibiotic hygromycin B include, for example, for in vitro cell selection.
(FR) La présente invention concerne une préparation d'hygromycine B antibiotique présentant une faible toxicité cellulaire et une grande pureté, et des procédés de préparation d'une telle préparation. Plus particulièrement, elle concerne une hygromycine B antibiotique isolée présentant une pureté supérieure à 98 % et des impuretés C, D et E individuellement inférieures à 0,5 % et une impureté F inférieure à 2 %, mesurées par CLHP. Les utilisations de cette hygromycine B antibiotique de grande pureté comprennent, par exemple, la sélection cellulaire in vitro.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)